Company research
Nexalin Technology, Inc.
CIK 1527352Updated Sep 24, 2026
SecurityNXL · NASDAQ · equity
Historical securities (1)
NXLIW · NASDAQ · warrant · closed Sep 20, 2025NXL price & chart
Loading TradingView…
NASDAQ:NXL on TradingView ↗About the company
We are a medical device company engaged in the design and development of innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. We developed an easy-to-administer medical device — referred to as “Generation 1” or “Gen-1” — that utilizes bioelectronic medical technology to treat anxiety, insomnia and depression without the need for drugs or psychotherapy. Our original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (the “FDA”) as a Class II device.
In the news
Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21 ↗
Seeking Alpha
NexLiving Communities reports Q4 results ↗
Recent filings
S-8 filing
S-1 filing
SCHEDULE 13D filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure
Items 3.03, 5.03, 7.01, 9.01
Show 5 more recent filings
SCHEDULE 13G filing
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03, 9.01
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 3.02, 9.01
424B5 filing
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 4,635,319Source | 4,222,732Source | 3,631,916Source | 7,432,136Source |
| Property, Plant and Equipment, NetUSD | — | — | — | 503Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 336,049Source | 260,727Source | 95,219Source | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 654,783Source | 574,485Source | 580,230Source | 162,743Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 81,571Source | 13,043Source | 9,369Source | 4,875Source |
| Inventory, NetUSD | 131,473Source | 174,578Source | 156,420Source | 154,370Source |
| Assets, CurrentUSD | 4,299,270Source | 3,961,141Source | 3,429,892Source | 7,425,462Source |
| Prepaid Expense and Other Assets, CurrentUSD | 363,014Source | 293,597Source | 315,670Source | 272,282Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | 496Source | 6,171Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 887,333Source | 546,694Source | 425,281Source | 1,953,449Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 19,186Source | 13,304Source | 7,437Source | 7,287Source |
| Additional Paid in CapitalUSD | 96,595,806Source | 88,308,478Source | 80,237,652Source | 77,824,427Source |
| Retained Earnings (Accumulated Deficit)USD | -92,867,412Source | -84,645,231Source | -77,038,049Source | -72,389,340Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 406Source | -513Source | -405Source | 36,313Source |
| Stockholders' Equity Attributable to ParentUSD | 3,747,986Source | 3,676,038Source | 3,206,635Source | 5,478,687Source |
| Liabilities and EquityUSD | 4,635,319Source | 4,222,732Source | 3,631,916Source | 7,432,136Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 887,333Source | 546,694Source | 425,281Source | 1,948,986Source |
| Operating Lease, Liability, CurrentUSD | — | — | 4,463Source | 50,797Source |
| Accounts Payable, CurrentUSD | 244,579Source | 155,949Source | 159,534Source | 658,367Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | 4,463Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 642,754Source | 390,745Source | 261,284Source | 539,822Source |
| Deferred Compensation EquityUSD | 589,000Source | 323,000Source | 215,000Source | 23,000Source |
| Short-term InvestmentsUSD | 3,068,429Source | 2,905,438Source | 2,368,203Source | 6,831,192Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -8,222,181Source | -7,607,182Source | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 3,123,263Source | 3,560,509Source | 2,413,375Source | 270,670Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 33,722Source | — | 880Source | -253Source |
| Increase (Decrease) in InventoriesUSD | -26,725Source | 18,158Source | 7,812Source | 142,852Source |
| Increase (Decrease) in Accounts PayableUSD | 88,629Source | -3,585Source | -238,833Source | -46,107Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -4,957,658Source | -3,944,390Source | -3,835,384Source | -2,215,699Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -131,991Source | -577,539Source | 4,452,872Source | -6,794,879Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 5,169,947Source | 4,516,184Source | -200,000Source | 8,511,543Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 654,783Source | 574,485Source | 580,230Source | 162,743Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Additional Financial Items | ||||
| AmortizationUSD | 21,537Source | 15,107Source | 3,751Source | — |
| Amortization of Intangible AssetsUSD | 21,538Source | — | — | — |
| DepreciationUSD | — | — | 503Source | 535Source |
| Gain (Loss) on Sale of InvestmentsUSD | 126,940Source | 130,110Source | 231,880Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 615,000Source | — |
| General and Administrative ExpenseUSD | 3,132,723Source | 2,553,459Source | — | — |
| Goodwill, Impairment LossUSD | 0Source | — | — | — |
| Inventory Write-downUSD | 16,380Source | 0Source | 5,762Source | 19,892Source |
| Net Income (Loss) Attributable to ParentUSD | -8,222,181Source | -7,607,182Source | -4,648,709Source | -1,697,816Source |
| Nonoperating Income (Expense)USD | 169,748Source | 142,613Source | 1,047,587Source | 135,215Source |
| Operating ExpensesUSD | 8,631,155Source | 7,886,774Source | 5,781,356Source | 2,791,176Source |
| Proceeds from Issuance of Common StockUSD | 4,646,397Source | 4,516,184Source | — | 8,545,270Source |
| Unrealized Gain (Loss) on InvestmentsUSD | 919Source | -108Source | -36,718Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 301,647Source | 168,721Source | 110,748Source | 1,321,357Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 4,398,241Source | 4,228,986Source | 3,818,842Source | 1,491,739Source |
| Operating Income (Loss)USD | -8,390,881Source | -7,754,646Source | -5,696,296Source | -1,833,031Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -8,221,133Source | -7,612,033Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -8,222,181Source | -7,607,182Source | -4,648,709Source | -1,697,816Source |
| Earnings Per Share, BasicUSD per share | -0.5Source | -0.83Source | -0.63Source | — |
| Earnings Per Share, DilutedUSD per share | -0.5Source | -0.83Source | -0.63Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 16,392,465Source | 9,215,772Source | 7,357,029Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 16,392,465Source | 9,215,772Source | 7,357,029Source | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 21,538Source | — | — | — |
| General and Administrative ExpenseUSD | 3,132,723Source | 2,553,459Source | — | — |
| Goodwill, Impairment LossUSD | 0Source | — | — | — |
| Gross ProfitUSD | 240,274Source | 132,128Source | 85,060Source | 958,145Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -8,221,263Source | — | — | — |
| Interest ExpenseUSD | -8,240Source | -3,193Source | 38,835Source | 59,382Source |
| Interest Income (Expense), NetUSD | -8,240Source | -3,193Source | — | — |
| Labor and Related ExpenseUSD | 1,879,283Source | 1,500,089Source | 1,387,916Source | 694,108Source |
| Marketing and Advertising ExpenseUSD | — | — | 11,214Source | 21,149Source |
| Nonoperating Income (Expense)USD | 169,748Source | 142,613Source | 1,047,587Source | 135,215Source |
| Operating ExpensesUSD | 8,631,155Source | 7,886,774Source | 5,781,356Source | 2,791,176Source |
| Other IncomeUSD | 34,568Source | 9,310Source | 239,542Source | 171,681Source |
| Research and Development ExpenseUSD | 1,083,522Source | 1,190,884Source | 1,922,000Source | 511,000Source |
Offerings
Registration 333-298744
Registration 333-286711
- Gross proceeds
- 5005000.0
- Net proceeds
- 4604600.0
- Deal price
- 1.3
- Shares
- 3850000
- Offering price
- $1.30
- Ticker
- NXL
Registration 333-283960
Filing attachments
nexalintech_ex107.htm · S-1 · 2026-09-03
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) N/A Nexalin Technology, Inc. (Exact Name of Registrant as Specified in its Charter) Security Security Fee Amount Proposed Maximum Fee Rate Amount of Type Class Calculation Registered(1) …
Read attachment ↗nexalintec_ex99-1.htm · 8-K · 2026-08-27
EX-99.1 3 nexalintec_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Nexalin Technology Announces Reverse Stock Split HOUSTON - August 27, 2026 - Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), announces that its board of directors has approved a 1-for-30 reverse stock split of the Company’s common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors …
Read attachment ↗nexalintec_ex4-1.htm · 8-K · 2026-08-20
EX-4.1 2 nexalintec_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT …
Read attachment ↗nexalintec_ex4-2.htm · 8-K · 2026-08-20
EX-4.2 3 nexalintec_ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT …
Read attachment ↗nexalintec_ex99-1.htm · 8-K · 2026-05-19
EX-99.1 2 nexalintec_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial Acquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture and virtual-care infrastructure already deployed at UCSD HOUSTON, TX, May 19, 2026, Nexalin Technology, Inc. (Nasdaq: NXL) (“Nexalin” or the “Company”), the leader in non-invasiv…
Read attachment ↗nexalintec_ex99-1.htm · 8-K · 2026-04-22
EX-99.1 2 nexalintec_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment 160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submission for moderate-to-severe insomnia HOUSTON - April 22, 2026 - Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced i…
Read attachment ↗